Applied Therapeutics, Inc. (APLT)
Upgrades & Downgrades
Latest APLT news
Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Applied Therapeutics shares were hammered this month after FDA did not agree to accelerated approval for its drug candidate AT-007 in treating galacto...
Why Applied Therapeutics Stock Is Sliding Today
The company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected.
The Motley Fool
Why Applied Therapeutics Shares Are Falling Today
Applied Therapeutics (NASDAQ: APLT) is trading significantly lower Monday after the company said it would not immediately submit a new drug applicatio...
Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder
Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for G...
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipelin...
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters
Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate
Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of...
Applied Therapeutics Reports Second Quarter 2021 Financial Results
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing
Applied Therapeutics Added to Russell Microcap® Index
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipelin...